CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts

Area of Science:

• Oncology
• Immunotherapy
• Pharmacovigilance

Background:

• Chimeric antigen receptor T-cell (CAR T) therapy has revolutionized cancer treatment.
• Increasing reports link CAR T treatment to secondary T-cell malignancies.
• Established pharmacovigilance methods struggle with causality assessment for these advanced therapies.

Purpose of the Study:

• To summarize case reports of secondary malignancies post-CAR T treatment.
• To discuss the rationale and challenges in causality assessment for these events.
• To explore pathophysiologic mechanisms and product-specific factors influencing risk.

Main Methods:

• Review and summary of existing case reports involving various CAR T products.
• Analysis of causality assessment challenges, considering patient and product-specific factors.
• Discussion of potential pathophysiologic pathways and contributing elements.

Main Results:

• Causality assessment is complicated by patient-specific risks and incomplete post-marketing data.
• Gene therapy products integrating into the host genome present unique challenges.
• A case-by-case approach is essential due to the complexity of cancer development.

Conclusions:

• Pharmacovigilance of advanced therapy medicinal products faces significant hurdles.
• Testing for vector presence, integration site, and gene expression is crucial for accurate assessment.
• Understanding contributing factors is vital for improving the safety of CAR T therapies.